MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paralysis; Alto-101, which is in a Phase II trial for schizophrenia; MRX-9FLT, which is in a Phase I trial for moderate to severe pain; and MRX-6LDT, which is in a drug formulation development stage for chronic pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Frequently asked questions
What sector does Medrx Co Ltd (4586) operate in?
Medrx Co Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Medrx Co Ltd (4586) current stock price?
As of the latest data, Medrx Co Ltd stock price is ¥65, with a previous close of ¥65.
What is Medrx Co Ltd (4586) current market capitalization?
Medrx Co Ltd market cap is approximately 3.86 billion.
What is Medrx Co Ltd (4586) Earnings Per Share (EPS)?
The trailing EPS is -¥17.
What is Medrx Co Ltd (4586) EBITDA?
Medrx Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -294.21 million.
Does Medrx Co Ltd (4586) pay dividends?
No. Medrx Co Ltd does not pay a dividend.
What is Medrx Co Ltd (4586) beta (volatility) score?
Medrx Co Ltd has a beta of 0.570, indicating lower volatility than the overall market.
